gemtuzumab [Gemtuzumab]

tematický
18
Termíny

gemtuzumab ozogamicin
gemtuzumab-ozogamicin
Mylotarg

 

CMA 676
CMA-676
Gemtuzumab Ozogamicin
Gemtuzumab-Ozogamicin
Mylotarg

Perzistentní odkaz   https://www.medvik.cz/link/D000079982
Definice

Imunotoxin, který sestává z monoklonální protilátky proti antigenu CD33 konjugované s kalicheamycinem. Používá se pro léčbu akutní myeloidní leukemie.

Immunotoxin that consists of an anti-CD33 (CD33 ANTIGEN) monoclonal antibody conjugated to CALICHEAMICIN. It is used for the treatment of ACUTE MYELOID LEUKEMIA.

DUI
D000079982 MeSH Prohlížeč
CUI
M0398183
Historická pozn.
2020 (2000)
Veřejná pozn.
2020; GEMTUZUMAB was indexed under AMINOGLYCOSIDES and ANTIBODIES, MONOCLONAL, HUMANIZED 2012-2019; and under ANTIBODIES, MONOCLONAL 2000-2011

Povolená podhesla

AN
analýza
AD
aplikace a dávkování 5
CH
chemie
HI
dějiny
EC
ekonomika 1
PK
farmakokinetika 1
PD
farmakologie 7
GE
genetika
IM
imunologie
IP
izolace a purifikace
CL
klasifikace
BL
krev
ME
metabolismus
UR
moč
CF
mozkomíšní mok
PO
otrava
AE
škodlivé účinky 4
TU
terapeutické užití 10
TO
toxicita 1
DE
účinky léků
RE
účinky záření
UL
ultrastruktura

D Chemikálie a léčiva
D09 sacharidy 724
D09.408 glykosidy 236
D09.408.051 aminoglykosidy 126
D09.408.051.247 kalicheamiciny 1
D09.408.051.247.500 gemtuzumab 18
D09.408.051.247.750 inotuzumab ozogamicin 12
D12 aminokyseliny, peptidy a proteiny 16
D12.776 proteiny 2 584
D12.776.124 krevní proteiny 910
D12.776.124.486 imunoproteiny 14
D12.776.124.486.485 imunoglobuliny 1 493
D12.776.124.486.485.114 protilátky 1 816
D12.776.124.486.485.114.224 monoklonální protilátky 4 693
D12.776.124.486.485.114.224.060 humanizované monoklonální protilátky 2 935
D12.776.124.486.485.114.224.060.125 abciximab 14
D12.776.124.486.485.114.224.060.250 adalimumab 353
D12.776.124.486.485.114.224.060.313 alemtuzumab 125
D12.776.124.486.485.114.224.060.344 basiliximab 2
D12.776.124.486.485.114.224.060.375 bevacizumab 453
D12.776.124.486.485.114.224.060.438 brentuximab vedotin 44
D12.776.124.486.485.114.224.060.500 certolizumab pegol 48
D12.776.124.486.485.114.224.060.750 cetuximab 186
D12.776.124.486.485.114.224.060.766 daklizumab 6
D12.776.124.486.485.114.224.060.782 denosumab 157
D12.776.124.486.485.114.224.060.790 gemtuzumab 18
D12.776.124.486.485.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.486.485.114.224.060.798 ipilimumab 267
D12.776.124.486.485.114.224.060.813 natalizumab 158
D12.776.124.486.485.114.224.060.829 nivolumab 459
D12.776.124.486.485.114.224.060.844 omalizumab 114
D12.776.124.486.485.114.224.060.860 palivizumab 13
D12.776.124.486.485.114.224.060.864 panitumumab 62
D12.776.124.486.485.114.224.060.866 ramucirumab 1
D12.776.124.486.485.114.224.060.868 ranibizumab 63
D12.776.124.486.485.114.224.060.875 trastuzumab 278
D12.776.124.486.485.114.224.060.937 ustekinumab 124
D12.776.124.790 sérové globuliny 61
D12.776.124.790.651 imunoglobuliny 1 493
D12.776.124.790.651.114 protilátky 1 816
D12.776.124.790.651.114.224 monoklonální protilátky 4 693
D12.776.124.790.651.114.224.060 humanizované monoklonální protilátky 2 935
D12.776.124.790.651.114.224.060.125 abciximab 14
D12.776.124.790.651.114.224.060.250 adalimumab 353
D12.776.124.790.651.114.224.060.375 alemtuzumab 125
D12.776.124.790.651.114.224.060.407 basiliximab 2
D12.776.124.790.651.114.224.060.438 bevacizumab 453
D12.776.124.790.651.114.224.060.469 brentuximab vedotin 44
D12.776.124.790.651.114.224.060.500 certolizumab pegol 48
D12.776.124.790.651.114.224.060.750 cetuximab 186
D12.776.124.790.651.114.224.060.766 daklizumab 6
D12.776.124.790.651.114.224.060.782 denosumab 157
D12.776.124.790.651.114.224.060.790 gemtuzumab 18
D12.776.124.790.651.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.790.651.114.224.060.798 ipilimumab 267
D12.776.124.790.651.114.224.060.813 natalizumab 158
D12.776.124.790.651.114.224.060.829 nivolumab 459
D12.776.124.790.651.114.224.060.844 omalizumab 114
D12.776.124.790.651.114.224.060.860 palivizumab 13
D12.776.124.790.651.114.224.060.864 panitumumab 62
D12.776.124.790.651.114.224.060.866 ramucirumab 1
D12.776.124.790.651.114.224.060.868 ranibizumab 63
D12.776.124.790.651.114.224.060.875 trastuzumab 278
D12.776.124.790.651.114.224.060.937 ustekinumab 124
D12.776.377 globuliny 68
D12.776.377.715 sérové globuliny 61
D12.776.377.715.548 imunoglobuliny 1 493
D12.776.377.715.548.114 protilátky 1 816
D12.776.377.715.548.114.224 monoklonální protilátky 4 693
D12.776.377.715.548.114.224.200 humanizované monoklonální protilátky 2 935
D12.776.377.715.548.114.224.200.125 abciximab 14
D12.776.377.715.548.114.224.200.250 adalimumab 353
D12.776.377.715.548.114.224.200.375 alemtuzumab 125
D12.776.377.715.548.114.224.200.407 basiliximab 2
D12.776.377.715.548.114.224.200.438 bevacizumab 453
D12.776.377.715.548.114.224.200.469 brentuximab vedotin 44
D12.776.377.715.548.114.224.200.500 certolizumab pegol 48
D12.776.377.715.548.114.224.200.750 cetuximab 186
D12.776.377.715.548.114.224.200.766 daklizumab 6
D12.776.377.715.548.114.224.200.782 denosumab 157
D12.776.377.715.548.114.224.200.790 gemtuzumab 18
D12.776.377.715.548.114.224.200.794 inotuzumab ozogamicin 12
D12.776.377.715.548.114.224.200.798 ipilimumab 267
D12.776.377.715.548.114.224.200.813 natalizumab 158
D12.776.377.715.548.114.224.200.829 nivolumab 459
D12.776.377.715.548.114.224.200.844 omalizumab 114
D12.776.377.715.548.114.224.200.860 palivizumab 13
D12.776.377.715.548.114.224.200.864 panitumumab 62
D12.776.377.715.548.114.224.200.866 ramucirumab 1
D12.776.377.715.548.114.224.200.868 ranibizumab 63
D12.776.377.715.548.114.224.200.875 trastuzumab 278
D12.776.377.715.548.114.224.200.937 ustekinumab 124

Přidat